Compare Novo Nordisk A/S (NVO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Williams-Sonoma, Inc. — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: Novo Nordisk A/S is far larger — about 5.9× Williams-Sonoma, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Williams-Sonoma, Inc. for 59 Days on average.
| NVO | WSM | |
|---|---|---|
Market Cap | $165.31B | $28.15B |
Volume | 11,432,838 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $251.81 |
52-Week Low | $35.29 | $168.64 |
Typical Hold Time | 116 Days | 59 Days |
Enterprise Value | $179.56B | $28.65B |
Dividend Yield | 4.71% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Profitability remains robust, with a net income margin of 14.73% and ROE of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook is positive, supported by raised full-year guidance and strong operational execution. Key opportunities include margin expansion and dividend growth, while risks involve housing market sensitivity and competitive pressures. Analyst consensus leans bullish with a $246.31 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
